Postdoctoral fellow at MD Anderson Cancer Center, USA; Chief Physician of the Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Executive Director of the Department of Urology, Jiading Branch of Renji Hospital. Mainly engaged in the clinical diagnosis, treatment, and research of urological tumors, especially prostate cancer; skilled in precise, painless, targeted prostate biopsy, robot-assisted/laparoscopic nerve-sparing radical prostatectomy for prostate cancer, ultra-minimally invasive precision ablation procedures for prostate cancer such as cryoablation/high-intensity focused ultrasound/nano-knife, molecular diagnosis and precision diagnosis and treatment of prostate cancer, individualized treatment of castration-resistant prostate cancer, and comprehensive diagnosis and treatment of neuroendocrine-differentiated prostate cancer, etc. Awarded the "2019 Young Talent" by the Urology Branch of Shanghai Medical Association, the "People's Good Doctor (Urological Oncology Field) Jinshan Camellia · Outstanding Contribution" title at the 2020 China Cancer Prevention and Treatment Annual Conference, the MDT Outstanding Physician of the Urogenital Tumor Committee of the Chinese Anti-Cancer Association in 2021 and 2022, and the CUA Young Outstanding Talent of the Chinese Urological Association in 2023; As a major contributor, won the First Prize of the 2021 Shanghai Medical Science and Technology Progress Award (2/10), the First Prize of the 2022 Science and Technology Award of the Ministry of Education (2/10), and the First Prize of the 2022 Shanghai Science and Technology Progress Award (2/11).